HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
Recruiting · NCT06513819 · Interventional (participants receive a specific treatment) · Lead sponsor: Yale University
View the official record on ClinicalTrials.gov →Interventions studied
Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique
What this trial is about
The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition.
Who can take part
Age range
50 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- HIV+
- have visited a local VA site in within the past year
- had an AUDIT-C indicating current alcohol use
- taking 5 or more non-ART medications, including an NCAM (i.e., benzodiazepines, opioids, muscle relaxants, sleeping medication, and selective serotonin reuptake inhibitors)
Exclusion criteria
- Inpatient individuals
- Patients with an Alcohol Use Disorder (AUD) diagnosis in the past 12 months
- Patients who test positive on the Alcohol Symptom Checklist for moderate or severe AUD during the screening process
Where it is running
1 location listed across 1 US state.
- VA Connecticut Healthcare System - West Haven, Connecticut, United States